# US 2006/0078535 A1 · Anticancer compounds and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0078535 A1
- Document ID: US20060078535A1
- Status: Published application
- Kind: A1
- Application number: 10/964,093
- Filed: 2004-10-13
- Published: 2006-04-13
- Earliest claimed: 2004-10-13
- Assignees: The Regents of the University of Michigan
- Inventors: Donna Livant
- Web page: https://patentgrep.com/patent/US20060078535A1

## CPC

- A61K 47/6949: {inclusion complexes, e.g. clathrates, cavitates or fullerenes}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The testing of tumor cells, including human tumors capable of metastases, in assays employing fibronectin-depleted substrates is described. Ex vivo induction of cells, including biopsied human cells, is performed with invasion-inducing agents. Additionally, anti-cancer chemotherapeutics are described. Specifically, chemotherapeutic agents which have anti-metastatic and anti-growth properties are described including non-peptide compositions of matter.

## Claims

### Claim 1

A composition comprising a dendrimer and at least one peptide comprising an amino acid sequence PHSCN (SEQ ID NO:86) attached to said dendrimer, wherein said dendrimer comprises branches.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said dendrimer comprises polylysine.

### Claim 3 (depends on 1)

The composition of claim 1, further comprising a chemotherapeutic agent attached to said dendrimer.

### Claim 4 (depends on 3)

The composition of claim 3, wherein said chemotherapeutic agent comprises methotrexate.

### Claim 5 (depends on 3)

The composition of claim 3, wherein said chemotherapeutic agent comprises boron.

### Claim 6 (depends on 3)

The composition of claim 3, wherein said chemotherapeutic agent comprises an antibody.

### Claim 7 (depends on 3)

The composition of claim 3, wherein said chemotherapeutic agent is selected from the group consisting of gemcitabine, 5-fluoruracil, a CDK inhibitor, a matrix metalloproteinase inhibitor, cisplatin, doxorubicin, estramustine, etoposide, docetaxel, paclitaxel, tamoxifen, and vincristine.

### Claim 8

A method, comprising:
a) providing;
i) a patient comprising a plurality of tumor cells; and
ii) a composition comprising a dendrimer and at least one peptide comprising an amino acid sequence PHSCN (SEQ ID NO:86) attached to said dendrimer; and
b) administering said composition to said patient under conditions such that at least a portion of said tumor cells undergo apoptosis.

### Claim 9 (depends on 8)

The method of claim 8, wherein said tumor cells comprise prostate tumor cells.

### Claim 10 (depends on 8)

The method of claim 8, wherein said patient further comprises tumor-associated blood vessels.

### Claim 11 (depends on 10)

The method of claim 10, wherein said blood vessels comprise endothelial cells.

### Claim 12 (depends on 8)

The method of claim 8, wherein said dendrimer further comprises a chemotherapeutic agent attached to said dendrimer.

### Claim 13 (depends on 12)

The method of claim 12, wherein said chemotherapeutic agent is selected from the group consisting of methotrexate, boron, an antibody, and a receptor.

### Claim 14

A method, comprising:
a) providing;
i) a patient comprising a plurality of metastatic tumor cells; and,
ii) a composition comprising a dendrimer and at least one peptide comprising an amino acid sequence PHSCN (SEQ ID NO:86) attached to said dendrimer, and;
b) administering said composition to said patient under conditions such that metastatic acitivity by said tumor cells is inhibited.

### Claim 15 (depends on 14)

The method of claim 14, wherein said tumor cells comprise prostate tumor cells.

### Claim 16 (depends on 14)

The method of claim 14, wherein said dendrimer further comprises a chemotherapeutic agent attached to said dendrimer.

### Claim 17 (depends on 16)

The method of claim 16, wherein said chemotherapeutic agent is selected from the group consisting of methotrexate, boron, an antibody, and a receptor.

### Claim 18 (depends on 16)

The method of claim 16, wherein said chemotherapeutic agent is selected from the group consisting of gemcitabine, 5-fluoruracil, a CDK inhibitor, a matrix metalloproteinase inhibitor, cisplatin, doxorubicin, estramustine, etoposide, docetaxel, paclitaxel, tamoxifen, and vincristine.
